Veracyte (VCYT) Common Equity (2012 - 2026)

Veracyte has disclosed Common Equity across 15 years of filings, most recently posting $1.3 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $1.3 billion, up 12.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 12.51% YoY), and the FY2025 annual result was $1.3 billion, up 11.36% from the prior year.
• Common Equity came in at $1.3 billion for Q1 2026 at Veracyte, up from $1.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $1.0 billion in Q4 2023.
• The 5-year median for Common Equity is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Common Equity retreated 5.32% in 2022 and rose 12.63% in 2024, its largest moves.
• Veracyte's Common Equity stood at $1.1 billion in 2022, then retreated by 2.89% to $1.0 billion in 2023, then grew by 12.63% to $1.2 billion in 2024, then gained by 11.36% to $1.3 billion in 2025, then rose by 2.66% to $1.3 billion in 2026.
• The last three Common Equity figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.